{
  "trial_id": "NCT02500901",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age \u2265 18 years at the time of consent.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 14 days prior to registration.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Documented histologically or cytologically confirmed adenocarcinoma of the prostate.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Ongoing androgen deprivation therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or bilateral orchiectomy.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Estimated life expectancy > 6 months",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior treatment of CRPC, including docetaxel, cabazitaxel, sipuleucel-T, or Radium-223 is allowed.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Documented metastatic disease with prostate-specific antigen (PSA) progression, radiographic progression, or both, despite receiving luteinizing hormone releasing hormone (LHRH) analogue therapy or orchiectomy with a serum testosterone level of 50 ng/dL or less.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "PSA progression is defined as three successive rising PSA values with an interval of at least one week between determinations.",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "Radiographic progression is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or at least two new lesions on bone scan.",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "At screening the serum testosterone must be 50 ng/dL or less and the PSA must be greater or equal to 2 ng/mL.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Prior chemotherapy must be completed at least 28 days prior to registration and the participant subject must have recovered from the acute toxic effects.",
      "label": "unknown",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "History of or active central nervous system (CNS) metastases. Subjects with neurological symptoms must undergo a head computed tomography (CT) scan or brain magnetic resonance imaging (MRI) to exclude brain metastasis.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Prior enzalutamide or other next-generation androgen receptor- (AR) targeting therapy.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior PARP-inhibitor therapy.",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient has a history of weight loss and persistent dry cough, with chest computed topography showing bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. He has been diagnosed with Wegener's granulomatosis and is being treated with corticosteroid and cyclophosphamides.",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT02500901",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}